As per our research analysis, the Middle East and African Diabetes Care Devices Market has been estimated at USD 1.36 billion in 2020 and is projected to reach USD 1.85 billion by 2025, at a CAGR of 6.34% during the forecast period. Diabetes is a group of metabolic disorders, chronic condition which is associated with an abnormally high level of sugar (glucose) in the blood. The Middle East and North Africa currently witness 35.4million people affected with Diabetes, which is going to reach 72.1 million by 2040. The rest of the Africa region witnesses 14.2 million people affected with diabetes, and this number is said to reach 34.2 million by 2040.
In Middle-East & Africa, the market is majorly driven with the rising awareness about disease care. With the increasing incidence of chronic diseases, there is an increase in demand leading to market growth. But the market here is mainly constrained due to low medical literacy. Health literacy influences essential health outcomes, including the acquisition of new disease-specific knowledge, improving self-efficacy, and adherence to self-care behaviors. Low health literacy has been consistently associated with worse diabetes knowledge in a variety of settings, including ambulatory and hospitalized patients.
Diabetes management modules will help in improving health literacy by enabling them to understand various diagnostics and devices. Therefore, health literacy improvement will help the emerging market like MEA to poise a good future in Diabetes Care Devices Market. Increasing the costs of medical devices is another constraint that’s restricting sales in this region. The high price of the devices is due to the technology involved in them. In most of the African countries, the reach of medical devices itself is challenging. On top of that, the high price of the devices is a tremendous burden for the customers, thus, restricting the sales of the devices in this region.
Noteworthy companies operating in the MEA Diabetes Care Devices Market are Roche Diagnostics, Johnson & Johnson, Abbott Laboratories, Novo Nordisk, Ascensia, Tandem, and Terumo.
This research report segmented and sub-segmented into the following categories:
By Type:
By Country:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Global Diabetes Care Devices Market, by Type
5.1.1 Glucose Monitoring Devices
5.1.1.1 Self Blood Glucose Monitoring Devices
5.1.1.1.1 Glucose Meters
5.1.1.1.2 Test strips
5.1.1.1.3 Lancets
5.1.1.1.4 Hemoglobin A1C testing Kits
5.1.1.2 Continuous Glucose Monitoring Devices
5.1.2 Insulin Delivery Systems
5.1.2.1 Insulin Syringes
5.1.2.2 Insulin Pens
5.1.2.3 Insulin Pumps
5.1.2.4 Jet Injectors
5.1.3 Control Solutions
6.1 Introduction
6.2 Middle-East
6.3 Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 F. Hoffmann-La Roche Ltd
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Medtronic Inc.
8.3 Johnson & Johnson
8.4 Abbott Laboratories
8.5 Becton, Dickinson and Company
8.6 Ascensia Diabetes care
8.7 Novo Nordisk A/S
8.8 Dexcom, Inc.
8.9 Insulet Corporation
8.10 Terumo Corporation
8.11 Tandem Diabetes Care, Inc
8.12 Ypsomed AG
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
